,disease,feature,therapy,text
0,Chronic Myelogenous Leukemia,Rearrangement,Bosutinib,"INDICATIONS AND USAGE-------------------------- with CML are diarrhea, abdominal pain, vomiting, nausea, rash, fatigue, BOSULIF is a kinase inhibitor indicated for the treatment of hepatic dysfunction, headache, pyrexia, decreased appetite respiratory tract 
infection, and constipation. The most common laboratory abnormalities • adult and pediatric patients 1 year of age and older with chronic phase Ph+ (≥20%) in adult and pediatric patients are creatinine increased, hemoglobin chronic myelogenous leukemia (CML), newly-diagnosed or resistant or decreased, lymphocyte count decreased, platelets decreased, ALT intolerant to prior therapy. (1) increased, calcium decreased, white blood cell count decreased, AST 
• adult patients with accelerated, or blast phase Ph+ CML with resistance or increased, absolute neutrophil count decreased, glucose increased, intolerance to prior therapy. (1) phosphorus decreased, urate increased, alkaline phosphatase increased, 
lipase increased, creatine kinase increased, and amylase increased. (6.1) ----------------------"
1,Chronic Myelogenous Leukemia,Rearrangement,Dasatinib,"INDICATIONS AND USAGE---------------------------- 
SPRYCEL is a kinase inhibitor indicated for the treatment of  
• newly diagnosed adults with Philadelphia chromosome-positive (Ph+) 
chronic myeloid leukemia (CML) in chronic phase. (1, 14) 
• adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ 
CML with resistance or intolerance to prior therapy including imatinib. (1, 
14) 
• adults with Philadelphia chromosome-positive acute lymphoblastic 
leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (1, 14) 
• pediatric patients 1 year of age and older with Ph+ CML in chronic phase. 
(1, 14) 
• pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in 
combination with chemotherapy. (1, 14) 
-----------------------"
3,Chronic Myelogenous Leukemia,Rearrangement,Imatinib,"INDICATIONS AND USAGE----------------------------
Gleevec is a kinase inhibitor indicated for the treatment of: 
•	 Newly diagnosed adult and pediatric patients with Philadelphia 
chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic 
phase (1.1) 
•	 Patients with Philadelphia chromosome positive chronic myeloid leukemia 
(Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase 
(CP) after failure of interferon-alpha therapy (1.2) 
•	 Adult patients with relapsed or refractory Philadelphia chromosome 
positive acute lymphoblastic leukemia (Ph+ ALL) (1.3) 
•	 Pediatric patients with newly diagnosed Philadelphia chromosome positive 
acute lymphoblastic leukemia (Ph+ ALL) in combination with 
chemotherapy (1.4) 
•	 Adult patients with myelodysplastic/myeloproliferative diseases 
(MDS/MPD) associated with PDGFR (platelet-derived growth factor 
receptor) gene re-arrangements (1.5) 
•	 Adult patients with aggressive systemic mastocytosis (ASM) without the 
D816V c-Kit mutation or with c-Kit mutational status unknown (1.6) 
•	 Adult patients with hypereosinophilic syndrome (HES) and/or chronic 
eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase 
(mutational analysis or FISH demonstration of CHIC2 allele deletion) and 
for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase 
negative or unknown (1.7) 
•	 Adult patients with unresectable, recurrent and/or metastatic 
dermatofibrosarcoma protuberans (DFSP) (1.8) 
•	 Patients with Kit (CD117) positive unresectable and/or metastatic 
malignant gastrointestinal stromal tumors (GIST) (1.9) 
•	 Adjuvant treatment of adult patients following resection of Kit (CD117) 
positive GIST (1.10) 
-----------------------"
5,Chronic Myeloid Leukemia,Rearrangement,Asciminib,"INDICATIONS AND USAGE-------------------------­
SCEMBLIX is a kinase inhibitor indicated for the treatment of adult patients 
with: 
•	 Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) 
in chronic phase (CP), previously treated with two or more tyrosine kinase 
inhibitors (TKIs). (1) 
This indication is approved under accelerated approval based on major 
molecular response (MMR).  Continued approval for this indication may be 
contingent upon verification and description of clinical benefit in a 
confirmatory trial(s). 
•	 Ph+ CML in CP with the T315I mutation. (1) 
----------------------"
6,Non-Small Cell Lung Cancer,Rearrangement,Alectinib,"INDICATIONS AND USAGE---------------------------­
ALECENSA is a kinase inhibitor indicated for the treatment of patients with 
anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung 
cancer (NSCLC) as detected by an FDA-approved test. (1) 
-----------------------"
7,Non-Small Cell Lung Cancer,Rearrangement,Crizotinib,"INDICATIONS AND USAGE----------------------------
XALKORI is a kinase inhibitor indicated for the treatment of 
 patients with metastatic non-small cell lung cancer (NSCLC) whose 
tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as 
detected by an FDA-approved test. (1.1, 2.1)
 pediatric patients 1 year of age and older and young adults with relapsed 
or refractory, systemic anaplastic large cell lymphoma (ALCL) that is 
ALK-positive. (1.2, 2.2) 
o Limitations of Use: The safety and efficacy of XALKORI have not
been established in older adults with relapsed or refractory, 
systemic ALK-positive ALCL.
 adult and pediatric patients 1 year of age and older with unresectable, 
recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that
is ALK-positive. (1.3, 2.2)
-----------------------"
8,Non-Small Cell Lung Cancer,Rearrangement,Lorlatinib,"INDICATIONS AND USAGE---------------------------- females of reproductive potential to use an effective non-hormonal 
LORBRENA is a kinase inhibitor indicated for the treatment of patients with method of contraception. (5.6, 7.2, 8.1, 8.3) 
anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung 
cancer (NSCLC) whose disease has progressed on ------------------------------ ADVERSE REACTIONS -----------------------------­
• crizotinib and at least one other ALK inhibitor for metastatic disease; or	 Most common adverse reactions (incidence ≥20%) are edema, peripheral 
•	 alectinib as the first ALK inhibitor therapy for metastatic disease; or neuropathy, cognitive effects, dyspnea, fatigue, weight gain, arthralgia, mood 
effects, and diarrhea. (6.1) •	 ceritinib as the first ALK inhibitor therapy for metastatic disease. 
This indication is approved under accelerated approval based on tumor To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at
response rate and duration of response. Continued approval for this indication 1-800-438-1985 or www.pfizer.com or FDA at 1-800-FDA-1088 or
may be contingent upon verification and description of clinical benefit in a www.fda.gov/medwatch.
confirmatory trial. (1)
------------------------------ DRUG INTERACTIONS------------------------------­
-----------------------"
9,Non-Small Cell Lung Cancer,Rearrangement,Ceritinib,"INDICATIONS AND USAGE--------------------------
ZYKADIA is a kinase inhibitor indicated for the treatment of adults with 
metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic 
lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (1, 
2.1) 
--------------------------"
10,Cholangiocarcinoma,Rearrangement,Pemigatinib,"INDICATIONS AND USAGE______________________ 
PEMAZYRE is a kinase inhibitor indicated: 
for the treatment of adults with previously treated, unresectable locally 
advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 
receptor 2 (FGFR2) fusion or other rearrangement as detected by an 
FDA-approved test. (1,2.1) 
This indication is approved under accelerated approval based on overall 
response rate and duration of response. Continued approval for this 
indication may be contingent upon verification and description of clinical 
benefit in a confirmatory trial(s). (1,2.1) 
For the treatment of adults with relapsed or refractory myeloid/lymphoid 
neoplasms (MLNs) with FGFR1 rearrangement. (1,2.1)"
12,Cholangiocarcinoma,Rearrangement,Infigratinib,"INDICATIONS AND USAGE-------------------------­
TRUSELTIQ is a kinase inhibitor indicated for the treatment of adults with 
previously treated, unresectable locally advanced or metastatic 
cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) 
fusion or other rearrangement as detected by an FDA-approved test. (1, 2.1) 
This indication is approved under accelerated approval based on overall 
response rate and duration of response. Continued approval for this indication 
may be contingent upon verification and description of clinical benefit in 
confirmatory trial(s). (1) 
------------------------"
13,Urothelial carcinoma,Rearrangement,Erdafitinib,"INDICATIONS AND USAGE---------------------------
BALVERSA is a kinase inhibitor indicated for the treatment of adult patients 
with locally advanced or metastatic urothelial carcinoma (mUC) with 
susceptible FGFR3 genetic alterations whose disease has progressed on or 
after at least one line of prior systemic therapy. 
Select patients for therapy based on an FDA-approved companion diagnostic 
for BALVERSA. (1, 2.1) 
Limitations of Use 
BALVERSA is not recommended for the treatment of patients who are 
eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (1, 
14.1) 
------------------------"
14,Any solid tumor,Rearrangement,Larotrectinib,"INDICATIONS AND USAGE--------------------------- 
VITRAKVI is a kinase inhibitor indicated for the treatment of adult and 
pediatric patients with solid tumors that: 
• have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a 
known acquired resistance mutation,  
• are metastatic or where surgical resection is likely to result in severe 
morbidity, and  
• have no satisfactory alternative treatments or that have progressed 
following treatment. 
This indication is approved under accelerated approval based on overall 
response rate and duration of response. Continued approval for this indication 
may be contingent upon verification and description of clinical benefit in 
confirmatory trials (1,14). 
----------------------"
15,Any solid tumor,Rearrangement,Entrectinib,"INDICATIONS AND USAGE----------------------------
ROZLYTREK is a kinase inhibitor indicated for the treatment of: 
• Adult patients with ROS1-positive metastatic non-small cell lung cancer 
(NSCLC) as detected by an FDA-approved test. (1.1) 
• Adult and pediatric patients older than 1 month of age with solid tumors 
that: 
o have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as 
detected by an FDA-approved test without a known acquired resistance 
mutation, 
o are metastatic or where surgical resection is likely to result in severe 
morbidity, and 
o have progressed following treatment or have no satisfactory alternative 
therapy. 
This indication is approved under accelerated approval based on tumor 
response rate and durability of response. Continued approval for this 
indication may be contingent upon verification and description of clinical 
benefit in the confirmatory trials. (1.2) 
-----------------------"
23,Non-Small Cell Lung Cancer,Rearrangement,Selpercatinib,"INDICATIONS AND USAGE ---------------------------
RETEVMO® is a kinase inhibitor indicated for the treatment of: 
• Adult patients with locally advanced or metastatic non-small cell lung 
cancer (NSCLC) with a rearranged during transfection (RET) gene 
fusion, as detected by an FDA-approved test (1.1) 
• Adult and pediatric patients 12 years of age and older with advanced 
or metastatic medullary thyroid cancer (MTC) with a RET mutation, as 
detected by an FDA-approved test, who require systemic therapy1 
(1.2) 
• Adult and pediatric patients 12 years of age and older with advanced 
or metastatic thyroid cancer with a RET gene fusion, as detected by an 
FDA-approved test, who require systemic therapy and who are 
radioactive iodine-refractory (if radioactive iodine is appropriate)1 (1.3) 
• Adult patients with locally advanced or metastatic solid tumors with a 
RET gene fusion that have progressed on or following prior systemic 
treatment or who have no satisfactory alternative treatment options1 
(1.4) 
This indication is approved under accelerated approval based on overall 
response rate and duration of response. Continued approval for this 
indication may be contingent upon verification and description of clinical 
benefit in confirmatory trial(s). 
------------------------"
25,Non-Small Cell Lung Cancer,Rearrangement,Pralsetinib,"INDICATIONS AND USAGE 
GAVRETO is a kinase inhibitor indicated for treatment of: 
• Adult patients with metastatic rearranged during transfection (RET) 
fusion-positive non-small cell lung cancer as detected by an FDA 
approved test (NSCLC). (1.1) 
• Adult and pediatric patients 12 years of age and older with advanced or 
metastatic RET fusion-positive thyroid cancer who require systemic 
therapy and who are radioactive iodine-refractory (if radioactive iodine 
is appropriate). 
This indication is approved under accelerated approval based on overall 
response rate and duration of response. Continued approval for this 
indication may be contingent upon verification and description of 
clinical benefit in confirmatory trial(s). (1.2) 
_______________"
28,Prostate Cancer,Somatic Variant,Olaparib,"INDICATIONS AND USAGE  --------------------------  
Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: 
Ovarian cancer 
• for the maintenance treatment of adult patients with deleterious or 
suspected deleterious germline or somatic BRCA-mutated advanced 
epithelial ovarian, fallopian tube or primary peritoneal cancer who are in 
complete or partial response to first-line platinum-based chemotherapy. 
Select patients for therapy based on an FDA-approved companion 
diagnostic for Lynparza. (1.1, 2.1) 
• in combination with bevacizumab for the maintenance treatment of adult 
patients with advanced epithelial ovarian, fallopian tube or primary 
peritoneal cancer who are in complete or partial response to first-line 
platinum-based chemotherapy and whose cancer is associated with 
homologous recombination deficiency (HRD)-positive status defined by 
either: 
• a deleterious or suspected deleterious BRCA mutation, and/or  
• genomic instability.  
Select patients for therapy based on an FDA-approved companion 
diagnostic for Lynparza (1.2, 2.1). 
• for the maintenance treatment of adult patients with recurrent epithelial 
ovarian, fallopian tube or primary peritoneal cancer, who are in 
complete or partial response to platinum-based chemotherapy. (1.3) 
Breast cancer 
• for the adjuvant treatment of adult patients with deleterious or suspected 
deleterious gBRCAm human epidermal growth factor receptor 2 
(HER2)-negative high risk early breast cancer who have been treated 
with neoadjuvant or adjuvant chemotherapy. Select patients for therapy 
based on an FDA-approved companion diagnostic for Lynparza. (1.4, 
2.1). 
• for the treatment of adult patients with deleterious or suspected 
deleterious gBRCAm, HER2-negative metastatic breast cancer who have 
been treated with chemotherapy in the neoadjuvant, adjuvant or 
metastatic setting. Patients with hormone receptor (HR)-positive breast 
cancer should have been treated with a prior endocrine therapy or be 
considered inappropriate for endocrine therapy. Select patients for 
therapy based on an FDA-approved companion diagnostic for Lynparza. 
(1.5, 2.1) 
Pancreatic cancer 
• for the maintenance treatment of adult patients with deleterious or 
suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma 
whose disease has not progressed on at least 16 weeks of a first-line 
platinum-based chemotherapy regimen. Select patients for therapy based 
on an FDA-approved companion diagnostic for Lynparza. (1.6, 2.1) 
Prostate cancer 
• for the treatment of adult patients with deleterious or suspected 
deleterious germline or somatic homologous recombination repair 
(HRR) gene-mutated metastatic castration-resistant prostate cancer 
(mCRPC) who have progressed following prior treatment with 
enzalutamide or abiraterone. Select patients for therapy based on an 
FDA-approved companion diagnostic for Lynparza. (1.7, 2.1) 
• in combination with abiraterone and prednisone or prednisolone for the 
treatment of adult patients with deleterious or suspected deleterious 
BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer 
(mCRPC). Select patients for therapy based on an FDA-approved 
companion diagnostic for Lynparza. (1.8, 2.1) 
 ----------------------"
30,Melanoma,Somatic Variant,Dabrafenib,"INDICATIONS AND USAGE----------------------------
TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of 
patients with unresectable or metastatic melanoma with BRAF V600E 
mutation as detected by an FDA-approved test. (1.1, 2.1) 
TAFINLAR is indicated, in combination with trametinib, for: 
• the treatment of patients with unresectable or metastatic melanoma with 
BRAF V600E or V600K mutations as detected by an FDA-approved test. 
(1.2, 2.1) 
• the adjuvant treatment of patients with melanoma with BRAF V600E or 
V600K mutations, as detected by an FDA-approved test, and involvement 
of lymph node(s), following complete resection. (1.3, 2.1) 
• the treatment of patients with metastatic non-small cell lung cancer 
(NSCLC) with BRAF V600E mutation as detected by an FDA-approved 
test. (1.4, 2.1) 
• the treatment of patients with locally advanced or metastatic anaplastic 
thyroid cancer (ATC) with BRAF V600E mutation and with no 
satisfactory locoregional treatment options. (1.5, 2.1) 
• the treatment of adult and pediatric patients 6 years of age and older with 
unresectable or metastatic solid tumors with BRAF V600E mutation who 
have progressed following prior treatment and have no satisfactory 
alternative treatment options. This indication is approved under 
accelerated approval based on overall response rate and duration of 
response. Continued approval for this indication may be contingent upon 
verification and description of clinical benefit in a confirmatory trial(s). 
(1.6, 2.1) 
• the treatment of pediatric patients 1 year of age and older with low-grade 
glioma (LGG) with a BRAF V600E mutation who require systemic 
therapy. (1.7, 2.1) 
Limitations of Use: TAFINLAR is not indicated for treatment of patients with 
colorectal cancer because of known intrinsic resistance to BRAF inhibition 
(1.8, 12.1). TAFINLAR is not indicated for treatment of patients with wild-
type BRAF solid tumors. (5.2) 
-----------------------"
36,Melanoma,Somatic Variant,Trametinib,"INDICATIONS AND USAGE-------------------------
MEKINIST is a kinase inhibitor indicated as a single agent for the treatment 
of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic 
melanoma with BRAF V600E or V600K mutations as detected by an FDA-
approved test. (1.1, 2.1) 
MEKINIST is indicated, in combination with dabrafenib, for: 
	 the treatment of patients with unresectable or metastatic melanoma with 
BRAF V600E or V600K mutations as detected by an FDA-approved 
test. (1.1, 2.1) 
	 the adjuvant treatment of patients with melanoma with BRAF V600E or 
V600K mutations, as detected by an FDA-approved test, and 
involvement of lymph node(s), following complete resection. (1.2, 2.1) 
	 the treatment of patients with metastatic non-small cell lung cancer 
(NSCLC) with BRAF V600E mutation as detected by an FDA-approved 
test. (1.3, 2.1) 
	 the treatment of patients with locally advanced or metastatic anaplastic 
thyroid cancer (ATC) with BRAF V600E mutation and with no 
satisfactory locoregional treatment options. (1.4, 2.1) 
-------------------------"
38,Melanoma,Somatic Variant,Encorafenib,"INDICATIONS AND USAGE-------------------------
BRAFTOVI is a kinase inhibitor indicated: 
 in combination with binimetinib, for the treatment of patients with 
unresectable or metastatic melanoma with a BRAF V600E or V600K 
mutation, as detected by an FDA-approved test. (1.1, 2.1)
 in combination with cetuximab, for the treatment of adult patients 
with metastatic colorectal cancer (CRC) with a BRAF V600E 
mutation, as detected by an FDA-approved test, after prior therapy. 
(1.2, 2.1)
 in combination with binimetinib, for the treatment of adult patients 
with metastatic non-small cell lung cancer (NSCLC) with a BRAF 
V600E mutation, as detected by an FDA-approved test. (1.3, 2.1)
Limitations of Use
BRAFTOVI is not indicated for treatment of patients with wild-type BRAF 
melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. (1.4, 5.2)
---------------------"
41,Melanoma,Somatic Variant,Vemurafenib,"INDICATIONS AND USAGE---------------------------­
•	 ZELBORAF® is a kinase inhibitor indicated for the treatment of patients 
with unresectable or metastatic melanoma with BRAF V600E mutation as 
detected by an FDA-approved test. (1.1, 2.1) 
•	 ZELBORAF® is indicated for the treatment of patients with Erdheim-
Chester Disease with BRAF V600 mutation. (1.2, 2.1) 
Limitation of Use: ZELBORAF is not indicated for treatment of patients with 
wild-type BRAF melanoma (2.1, 5.2) 
-----------------------"
45,Ovarian Cancer,Somatic Variant,Rucaparib,"INDICATIONS AND USAGE---------------------------­
RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: 
Ovarian cancer 
•	 for the maintenance treatment of adult patients with recurrent epithelial 
ovarian, fallopian tube, or primary peritoneal cancer who are in a complete 
or partial response to platinum-based chemotherapy. (1.1) 
•	 for the treatment of adult patients with a deleterious BRCA mutation 
(germline and/or somatic)-associated epithelial ovarian, fallopian tube, or 
primary peritoneal cancer who have been treated with two or more 
chemotherapies. Select patients for therapy based on an FDA-approved 
companion diagnostic for RUBRACA. (1.1, 2.1) 
Prostate cancer 
•	 for the treatment of adult patients with a deleterious BRCA mutation 
(germline and/or somatic)-associated metastatic castration-resistant prostate 
cancer (mCRPC) who have been treated with androgen receptor-directed 
therapy and a taxane-based chemotherapy. Select patients for therapy based 
on an FDA-approved companion diagnostic for RUBRACA. (1.2, 2.1) 
This indication is approved under accelerated approval based on objective 
response rate and duration of response. Continued approval for this 
indication may be contingent upon verification and description of clinical 
benefit in confirmatory trials. (1.2) 
-----------------------"
48,Ovarian Cancer,Somatic Variant,Niraparib,"INDICATIONS AND USAGE 
ZEJULA is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated: 
 for the maintenance treatment of adult patients with advanced 
epithelial ovarian, fallopian tube, or primary peritoneal cancer who 
are in a complete or partial response to first-line platinum-based 
chemotherapy. (1.1) 
 for the maintenance treatment of adult patients with recurrent 
epithelial ovarian, fallopian tube, or primary peritoneal cancer who 
are in a complete or partial response to platinum-based 
chemotherapy. (1.2) 
 for the treatment of adult patients with advanced ovarian, fallopian 
tube, or primary peritoneal cancer who have been treated with three 
or more prior chemotherapy regimens and whose cancer is 
associated with homologous recombination deficiency (HRD) 
positive status defined by either: 
	 a deleterious or suspected deleterious BRCA mutation, or 
	 genomic instability and who have progressed more than six 
months after response to the last platinum-based 
chemotherapy. 
Select patients for therapy based on an FDA-approved companion 
diagnostic for ZEJULA. (1.3, 2.1)"
72,Non-Small Cell Lung Cancer,Somatic Variant,Osimertinib,"INDICATIONS AND USAGE --------------------------
TAGRISSO is a kinase inhibitor indicated for: 
 adjuvant therapy after tumor resection in adult patients with non-small 
cell lung cancer (NSCLC) whose tumors have epidermal growth factor 
receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as 
detected by an FDA-approved test (1.1, 2.2) 
 the first-line treatment of adult patients with metastatic NSCLC whose 
tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as 
detected by an FDA-approved test. (1.2, 2.2) 
 in combination with pemetrexed and platinum-based chemotherapy, the 
first-line treatment of adult patients with locally advanced or metastatic 
NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R 
mutations, as detected by an FDA-approved test. (1.3, 2.2) 
 the treatment of adult patients with metastatic EGFR T790M mutation-
positive NSCLC, as detected by an FDA-approved test, whose disease has 
progressed on or after EGFR TKI therapy. (1.4, 2.2) 
----------------------"
73,Non-Small Cell Lung Cancer,Somatic Variant,Afatinib,"INDICATIONS AND USAGE--------------------------­
GILOTRIF is a kinase inhibitor indicated for: 
•	 First-line treatment of patients with metastatic non-small cell lung cancer 
(NSCLC) whose tumors have non-resistant epidermal growth factor 
receptor (EGFR) mutations as detected by an FDA-approved test (1.1) 
Limitations of Use: Safety and efficacy of GILOTRIF were not established 
in patients whose tumors have resistant EGFR mutations (1.1) 
•	 Treatment of patients with metastatic, squamous NSCLC progressing after 
platinum-based chemotherapy (1.2) 
----------------------"
78,Non-Small Cell Lung Cancer,Somatic Variant,Amivantamab-vmjw,"INDICATIONS AND USAGE---------------------------
RYBREVANT is a bispecific EGF receptor-directed and MET receptor-
directed antibody indicated: 
• in combination with carboplatin and pemetrexed for the first-line treatment 
of adult patients with locally advanced or metastatic non-small cell lung cancer 
(NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion 
mutations, as detected by an FDA-approved test. (1, 2.2) 
• as a single agent for the treatment of adult patients with locally advanced or 
metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an 
FDA-approved test, whose disease has progressed on or after platinum-based 
chemotherapy. (1, 2.2) 
------------------------"
79,Non-Small Cell Lung Cancer,Somatic Variant,Mobocertinib,"INDICATIONS AND USAGE--------------------------­
EXKIVITY is a kinase inhibitor indicated for the treatment of adult 
patients with locally advanced or metastatic non-small cell lung cancer 
(NSCLC) with epidermal growth factor receptor (EGFR) exon 20 
insertion mutations, as detected by an FDA-approved test, whose 
disease has progressed on or after platinum-based chemotherapy. 
This indication is approved under accelerated approval based on 
overall response rate and duration of response. Continued approval for 
this indication may be contingent upon verification and description of 
clinical benefit in confirmatory trial(s). (1, 2.1) 
------------------------"
80,Follicular Lymphoma,Somatic Variant,Tazemetostat,"INDICATIONS AND USAGE -------------------------­
TAZVERIK is a methyltransferase inhibitor indicated for the treatment of: 
•	 Adults and pediatric patients aged 16 years and older with metastatic or 
locally advanced epithelioid sarcoma not eligible for complete resection. 
(1.1) 
•	 Adult patients with relapsed or refractory follicular lymphoma whose 
tumors are positive for an EZH2 mutation as detected by an 
FDA-approved test and who have received at least 2 prior systemic 
therapies. (1.2) 
•	 Adult patients with relapsed or refractory follicular lymphoma who have 
no satisfactory alternative treatment options. (1.2) 
These indications are approved under accelerated approval based on overall 
response rate and duration of response. Continued approval for these 
indications may be contingent upon verification and description of clinical 
benefit in a confirmatory trial(s). 
-----------------------"
90,Acute Myeloid Leukemia,Somatic Variant,Ivosidenib,"INDICATIONS AND USAGE------------------------------ 
TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for 
patients with a susceptible IDH1 mutation as detected by an FDA-approved test 
with: 
Newly Diagnosed Acute Myeloid Leukemia (AML) 
• In combination with azacitidine or as monotherapy for the treatment of newly 
diagnosed AML in adults 75 years or older, or who have comorbidities that 
preclude use of intensive induction chemotherapy (1.1).   
Relapsed or refractory AML  
• For the treatment of adult patients with relapsed or refractory AML (1.2). 
Relapsed or refractory Myelodysplastic Syndromes (MDS)  
• For the treatment of adult patients with relapsed or refractory 
myelodysplastic syndromes (1.3). 
Locally Advanced or Metastatic Cholangiocarcinoma 
• For the treatment of adult patients with locally advanced or metastatic 
cholangiocarcinoma who have been previously treated (1.4). 
-----------------------"
97,Acute Myeloid Leukemia,Somatic Variant,Enasidenib,"INDICATIONS AND USAGE----------------------------
IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment 
of adult patients with relapsed or refractory acute myeloid leukemia (AML) 
with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-
approved test (1.1). 
-----------------------"
102,Gastrointestinal Stromal Tumor,Somatic Variant,Regorafenib,"INDICATIONS AND USAGE -------------------------­
STIVARGA is a kinase inhibitor indicated for the treatment of patients with: 
• Metastatic colorectal cancer (CRC) who have been previously treated with 
fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-
VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. (1.1) 
• Locally advanced, unresectable or metastatic gastrointestinal stromal tumor 
(GIST) who have been previously treated with imatinib mesylate and 
sunitinib malate. (1.2) 
• Hepatocellular carcinoma (HCC) who have been previously treated with 
sorafenib (1.3) 
----------------------"
106,Gastrointestinal Stromal Tumor,Somatic Variant,Sunitinib,"INDICATIONS AND USAGE---------------------------­
SUTENT is a kinase inhibitor indicated for: 
•	 treatment of adult patients with gastrointestinal stromal tumor (GIST) 
after disease progression on or intolerance to imatinib mesylate. (1.1) 
•	 treatment of adult patients with advanced renal cell carcinoma (RCC). 
(1.2) 
•	 adjuvant treatment of adult patients at high risk of recurrent RCC 
following nephrectomy. (1.3) 
•	 treatment of progressive, well-differentiated pancreatic neuroendocrine 
tumors (pNET) in adult patients with unresectable locally advanced or 
metastatic disease. (1.4) 
-----------------------"
109,Non-Small Cell Lung Cancer,Somatic Variant,Sotorasib,"INDICATIONS AND USAGE--------------------------­
LUMAKRAS is an inhibitor of the RAS GTPase family indicated for the 
treatment of adult patients with KRAS G12C-mutated locally advanced or 
metastatic non-small cell lung cancer (NSCLC), as determined by an 
FDA-approved test, who have received at least one prior systemic therapy. (1) 
This indication is approved under accelerated approval based on overall 
response rate (ORR) and duration of response (DOR). Continued approval for 
this indication may be contingent upon verification and description of clinical 
benefit in a confirmatory trial(s). (1) 
----------------------"
110,Non-Small Cell Lung Cancer,Somatic Variant,Capmatinib,"INDICATIONS AND USAGE 
TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose 
tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-
approved test.   
2"
113,Gastrointestinal Stromal Tumor,Somatic Variant,Avapritinib,"INDICATIONS AND USAGE--------------------------­
AYVAKIT is a kinase inhibitor indicated for: 
Gastrointestinal Stromal Tumor (GIST) 
•	 the treatment of adults with unresectable or metastatic GIST 
harboring a platelet-derived growth factor receptor alpha 
(PDGFRA) exon 18 mutation, including PDGFRA D842V 
mutations. (1.1, 2.1) 
Advanced Systemic Mastocytosis (AdvSM) 
•	 the treatment of adult patients with AdvSM. AdvSM includes 
patients with aggressive systemic mastocytosis (ASM), systemic 
mastocytosis with an associated hematological neoplasm (SM­
AHN), and mast cell leukemia (MCL). (1.2) 
•	 Limitations of Use: AYVAKIT is not recommended for the 
treatment of patients with AdvSM with platelet counts of less than 
50 X 109/L (1.2) 
-----------------------"
115,Breast Cancer,Somatic Variant,Alpelisib,"INDICATIONS AND USAGE-------------------------­
PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the 
treatment of postmenopausal women, and men, with hormone receptor (HR)­
positive, human epidermal growth factor receptor 2 (HER2)-negative, 
PIK3CA-mutated, advanced or metastatic breast cancer as detected by an 
FDA-approved test following progression on or after an endocrine-based 
regimen. (1) 
----------------------"
121,Subependymal giant cell astrocytoma,Somatic Variant,Everolimus,"INDICATIONS AND USAGE---------------------------
AFINITOR is a kinase inhibitor indicated for the treatment of: 
	 Postmenopausal women with advanced hormone receptor-positive, HER2-
negative breast cancer in combination with exemestane after failure of 
treatment with letrozole or anastrozole. (1.1) 
	 Adults with progressive neuroendocrine tumors of pancreatic origin 
(PNET) and adults with progressive, well-differentiated, non-functional 
neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that 
are unresectable, locally advanced or metastatic. 
Limitations of Use: AFINITOR is not indicated for the treatment of 
patients with functional carcinoid tumors. (1.2) 
 Adults with advanced renal cell carcinoma (RCC) after failure of treatment 
with sunitinib or sorafenib. (1.3) 
 Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), 
not requiring immediate surgery. (1.4) 
AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the 
treatment of adult and pediatric patients aged 1 year and older with TSC who 
have subependymal giant cell astrocytoma (SEGA) that requires therapeutic 
intervention but cannot be curatively resected. (1.5) 
AFINITOR DISPERZ is a kinase inhibitor indicated for the adjunctive 
treatment of adult and pediatric patients aged 2 years and older with TSC-
associated partial-onset seizures. (1.6) 
------------------------"
130,Breast Cancer,Germline Variant,Talazoparib,"INDICATIONS AND USAGE----------------------------
TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated 
for: 
Breast Cancer 
• As a single agent, for the treatment of adult patients with deleterious or 
suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative 
locally advanced or metastatic breast cancer. Select patients for therapy 
based on an FDA-approved companion diagnostic for TALZENNA. (1.1) 
HRR Gene-mutated mCRPC 
• In combination with enzalutamide for the treatment of adult patients with 
HRR gene-mutated metastatic castration-resistant prostate cancer 
(mCRPC). (1.2) 
----------------------"
144,Breast Cancer,Copy Number,Ado-Trastuzumab Emtansine,"INDICATIONS AND USAGE 
KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate 
indicated, as a single agent, for: 
•	 the treatment of patients with HER2-positive, metastatic breast cancer 
who previously received trastuzumab and a taxane, separately or in 
combination. Patients should have either: 
•	 received prior therapy for metastatic disease, or 
•	 developed disease recurrence during or within six months of 
completing adjuvant therapy. (1.1) 
•	 the adjuvant treatment of patients with HER2-positive early breast cancer 
who have residual invasive disease after neoadjuvant taxane and 
trastuzumab-based treatment. (1.2) 
Select patients for therapy based on an FDA-approved companion diagnostic 
for KADCYLA [see Dosage and Administration (2.1)] 
"
145,Breast Cancer,Copy Number,Lapatinib,"INDICATIONS AND USAGE------------------------------ 
TYKERB is a kinase inhibitor indicated in combination with: (1) 
 capecitabine for the treatment of patients with advanced or metastatic breast 
cancer whose tumors overexpress human epidermal growth factor receptor 2 
(HER2) and who have received prior therapy including an anthracycline, a 
taxane, and trastuzumab. 
Limitations of Use: Patients should have disease progression on trastuzumab 
prior to initiation of treatment with TYKERB in combination with capecitabine. 
 letrozole for the treatment of postmenopausal women with hormone receptor-
positive metastatic breast cancer that overexpresses the HER2 receptor for 
whom hormonal therapy is indicated. 
TYKERB in combination with an aromatase inhibitor has not been compared to a 
trastuzumab-containing chemotherapy regimen for the treatment of metastatic 
breast cancer. 
----------------------------"
147,Breast Cancer,Copy Number,Neratinib,"INDICATIONS AND USAGE 
NERLYNX is a kinase inhibitor indicated: 
•	 As a single agent, for the extended adjuvant treatment of adult patients with 
early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab­
based therapy. (1.1) 
•	 In combination with capecitabine, for the treatment of adult patients with 
advanced or metastatic HER2-positive breast cancer who have received 
two or more prior anti-HER2 based regimens in the metastatic setting. (1.2) 
_______________"
148,Breast Cancer,Copy Number,Pertuzumab + Trastuzumab,"INDICATIONS AND USAGE---------------------------­
PERJETA is a HER2/neu receptor antagonist indicated for: 
•	 Use in combination with trastuzumab and docetaxel for treatment of 
patients with HER2-positive metastatic breast cancer (MBC) who have 
not received prior anti-HER2 therapy or chemotherapy for metastatic 
disease. (1.1) 
•	 Use in combination with trastuzumab and chemotherapy as 
o	 neoadjuvant treatment of patients with HER2-positive, locally 
advanced, inflammatory, or early stage breast cancer (either greater 
than 2 cm in diameter or node positive) as part of a complete 
treatment regimen for early breast cancer. (1.2, 2.2, 14.2) 
o	 adjuvant treatment of patients with HER2-positive early breast cancer 
at high risk of recurrence (1.2, 2.2, 14.3) 
-----------------------"
149,Breast Cancer,Copy Number,Trastuzumab,"INDICATIONS AND USAGE----------------------------
Herceptin is a HER2/neu receptor antagonist indicated for: 
•	 The treatment of HER2-overexpressing breast cancer. (1.1, 1.2) 
•	 The treatment of HER2-overexpressing metastatic gastric or 
gastroesophageal junction adenocarcinoma. (1.3) 
Select patients for therapy based on an FDA-approved companion diagnostic 
for Herceptin (1, 2.1). 
------------------------"
152,Breast Cancer,Copy Number,Capecitabine + Trastuzumab + Tucatinib,"INDICATIONS AND USAGE -----------------------------
TUKYSA is a kinase inhibitor indicated: 
• in combination with trastuzumab and capecitabine for treatment of adult 
patients with advanced unresectable or metastatic HER2-positive breast 
cancer, including patients with brain metastases, who have received one 
or more prior anti-HER2-based regimens in the metastatic setting. (1.1) 
• in combination with trastuzumab for the treatment of adult patients with 
RAS wild-type HER2-positive unresectable or metastatic colorectal 
cancer that has progressed following treatment with fluoropyrimidine-, 
oxaliplatin-, and irinotecan-based chemotherapy. (1.2) 
This indication is approved under accelerated approval based on tumor 
response rate and durability of response [see Clinical Studies (14.2)]. 
Continued approval for this indication may be contingent upon 
verification and description of clinical benefit in confirmatory trials. 
----------------------"
153,Breast Cancer,Copy Number,Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab,"INDICATIONS AND USAGE 
PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu 
receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: 
•	 Use in combination with chemotherapy as: 
o	 neoadjuvant treatment of patients with HER2-positive, locally 
advanced, inflammatory, or early stage breast cancer (either greater 
than 2 cm in diameter or node positive) as part of a complete 
treatment regimen for early breast cancer. (1.1) 
o	 adjuvant treatment of patients with HER2-positive early breast 
cancer at high risk of recurrence (1.1) 
•	 Use in combination with docetaxel for treatment of patients with HER2­
positive metastatic breast cancer (MBC) who have not received prior 
anti-HER2 therapy or chemotherapy for metastatic disease. (1.2) 
"
155,Breast Cancer,Copy Number,Margetuximab-cmkb + Chemotherapy,"INDICATIONS AND USAGE---------------------------­
MARGENZA is a HER2/neu receptor antagonist indicated, in combination 
with chemotherapy, for the treatment of adult patients with metastatic HER2­
positive breast cancer who have received two or more prior anti-HER2 
regimens, at least one of which was for metastatic disease. (1, 2.1, 14.1) 
------------------------"
156,Gastic Adenocarcinoma,Copy Number,Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum,"INDICATIONS AND USAGE----------------------------
KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking 
antibody indicated: 
Melanoma 
• for the treatment of patients with unresectable or metastatic 
melanoma. (1.1) 
• for the adjuvant treatment of adult and pediatric (12 years and 
older) patients with Stage IIB, IIC, or III melanoma following 
complete resection. (1.1) 
Non-Small Cell Lung Cancer (NSCLC) 
• in combination with pemetrexed and platinum chemotherapy, 
as first-line treatment of patients with metastatic nonsquamous 
NSCLC, with no EGFR or ALK genomic tumor aberrations. 
(1.2) 
• in combination with carboplatin and either paclitaxel or 
paclitaxel protein-bound, as first-line treatment of patients with 
metastatic squamous NSCLC. (1.2) 
• as a single agent for the first-line treatment of patients with 
NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) 
≥1%] as determined by an FDA-approved test, with no EGFR 
or ALK genomic tumor aberrations, and is: 
o Stage III where patients are not candidates for surgical 
resection or definitive chemoradiation, or 
o metastatic. (1.2, 2.1) 
• as a single agent for the treatment of patients with metastatic 
NSCLC whose tumors express PD-L1 (TPS ≥1%) as 
determined by an FDA-approved test, with disease 
progression on or after platinum-containing chemotherapy. 
Patients with EGFR or ALK genomic tumor aberrations should 
have disease progression on FDA-approved therapy for these 
aberrations prior to receiving KEYTRUDA. (1.2, 2.1) 
• for the treatment of patients with resectable (tumors ≥4 cm or 
node positive) NSCLC in combination with platinum-containing 
chemotherapy as neoadjuvant treatment, and then continued 
as a single agent as adjuvant treatment after surgery. (1.2) 
• as a single agent, for adjuvant treatment following resection 
and platinum-based chemotherapy for adult patients with 
Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. (1.2) 
Head and Neck Squamous Cell Cancer (HNSCC) 
• in combination with platinum and FU for the first-line treatment 
of patients with metastatic or with unresectable, recurrent 
HNSCC. (1.3) 
• as a single agent for the first-line treatment of patients with 
metastatic or with unresectable, recurrent HNSCC whose 
tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as 
determined by an FDA-approved test. (1.3, 2.1) 
• as a single agent for the treatment of patients with recurrent or 
metastatic HNSCC with disease progression on or after 
platinum-containing chemotherapy. (1.3) 
Classical Hodgkin Lymphoma (cHL) 
• for the treatment of adult patients with relapsed or refractory 
cHL. (1.4) 
• for the treatment of pediatric patients with refractory cHL, or 
cHL that has relapsed after 2 or more lines of therapy. (1.4) 
Primary Mediastinal Large B-Cell Lymphoma (PMBCL) 
• for the treatment of adult and pediatric patients with refractory 
PMBCL, or who have relapsed after 2 or more prior lines of 
therapy. (1.5) 
• Limitations of Use: KEYTRUDA is not recommended for 
treatment of patients with PMBCL who require urgent 
cytoreductive therapy. 
Urothelial Carcinoma 
• in combination with enfortumab vedotin, for the treatment of 
adult patients with locally advanced or metastatic urothelial 
carcinoma who are not eligible for cisplatin-containing 
chemotherapy.1 (1.6) 
• as a single agent for the treatment of patients with locally 
advanced or metastatic urothelial carcinoma who: 
o are not eligible for any platinum-containing 
chemotherapy, or 
o who have disease progression during or following 
platinum-containing chemotherapy or within 12 months of 
neoadjuvant or adjuvant treatment with platinum-
containing chemotherapy. (1.6) 
• as a single agent for the treatment of patients with Bacillus 
Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle 
invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) 
with or without papillary tumors who are ineligible for or have 
elected not to undergo cystectomy. (1.6) 
Microsatellite Instability-High or Mismatch Repair Deficient Cancer 
• for the treatment of adult and pediatric patients with 
unresectable or metastatic microsatellite instability-high 
(MSI-H) or mismatch repair deficient (dMMR) solid tumors, as 
determined by an FDA-approved test, that have progressed 
following prior treatment and who have no satisfactory 
alternative treatment options. (1.7, 2.1) 
Microsatellite Instability-High or Mismatch Repair Deficient 
Colorectal Cancer (CRC) 
• for the treatment of patients with unresectable or metastatic 
MSI-H or dMMR colorectal cancer (CRC) as determined by an 
FDA-approved test. (1.8, 2.1) 
Gastric Cancer 
• in combination with trastuzumab, fluoropyrimidine- and 
platinum-containing chemotherapy, for the first-line treatment 
of patients with locally advanced unresectable or metastatic 
HER2-positive gastric or gastroesophageal junction (GEJ) 
adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as 
determined by an FDA-approved test.1 (1.9) 
Esophageal Cancer 
• for the treatment of patients with locally advanced or metastatic 
esophageal or gastroesophageal junction (GEJ) (tumors with 
epicenter 1 to 5 centimeters above the GEJ) carcinoma that is 
not amenable to surgical resection or definitive chemoradiation 
either: 
o in combination with platinum- and fluoropyrimidine-based 
chemotherapy, or 
o as a single agent after one or more prior lines of systemic 
therapy for patients with tumors of squamous cell 
histology that express PD-L1 (CPS ≥10) as determined 
by an FDA-approved test. (1.10, 2.1) 
Cervical Cancer 
• in combination with chemotherapy, with or without 
bevacizumab, for the treatment of patients with persistent, 
recurrent, or metastatic cervical cancer whose tumors express 
PD-L1 (CPS ≥1) as determined by an FDA-approved test. 
(1.11, 2.1) 
• as a single agent for the treatment of patients with recurrent or 
metastatic cervical cancer with disease progression on or after 
chemotherapy whose tumors express PD-L1 (CPS ≥1) as 
determined by an FDA-approved test. (1.11, 2.1) 
Hepatocellular Carcinoma (HCC) 
• for the treatment of patients with HCC who have been 
previously treated with sorafenib.1 (1.12) 
Biliary Tract Cancer (BTC) 
• in combination with gemcitabine and cisplatin, for the 
treatment of patients with locally advanced unresectable or 
metastatic biliary tract cancer. (1.13) 
Merkel Cell Carcinoma (MCC) 
• for the treatment of adult and pediatric patients with recurrent 
locally advanced or metastatic Merkel cell carcinoma. (1.14) 
Renal Cell Carcinoma (RCC) 
• in combination with axitinib, for the first-line treatment of adult 
patients with advanced RCC. (1.15) 
• in combination with lenvatinib, for the first-line treatment of 
adult patients with advanced RCC. (1.15) 
• for the adjuvant treatment of patients with RCC at 
intermediate-high or high risk of recurrence following 
Reference ID: 5274826 
This label may not be the latest approved by FDA.  
For current labeling information, please visit https://www.fda.gov/drugsatfda  
nephrectomy, or following nephrectomy and resection of 
metastatic lesions. (1.15) 
Endometrial Carcinoma 
• in combination with lenvatinib, for the treatment of patients with 
advanced endometrial carcinoma that is mismatch repair 
proficient (pMMR) as determined by an FDA-approved test or 
not MSI-H, who have disease progression following prior 
systemic therapy in any setting and are not candidates for 
curative surgery or radiation. (1.16, 2.1) 
• as a single agent, for the treatment of patients with advanced 
endometrial carcinoma that is MSI-H or dMMR, as determined 
by an FDA-approved test, who have disease progression 
following prior systemic therapy in any setting and are not 
candidates for curative surgery or radiation. (1.16, 2.1) 
Tumor Mutational Burden-High (TMB-H) Cancer 
• for the treatment of adult and pediatric patients with 
unresectable or metastatic tumor mutational burden-high 
(TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as 
determined by an FDA-approved test, that have progressed 
following prior treatment and who have no satisfactory 
alternative treatment options.1 (1.17, 2.1) 
• Limitations of Use: The safety and effectiveness of 
KEYTRUDA in pediatric patients with TMB-H central nervous 
system cancers have not been established. 
Cutaneous Squamous Cell Carcinoma (cSCC) 
• for the treatment of patients with recurrent or metastatic cSCC 
or locally advanced cSCC that is not curable by surgery or 
radiation. (1.18) 
Triple-Negative Breast Cancer (TNBC) 
• for the treatment of patients with high-risk early-stage TNBC in 
combination with chemotherapy as neoadjuvant treatment, and 
then continued as a single agent as adjuvant treatment after 
surgery. (1.19) 
• in combination with chemotherapy, for the treatment of 
patients with locally recurrent unresectable or metastatic 
TNBC whose tumors express PD-L1 (CPS ≥10) as determined 
by an FDA approved test. (1.19, 2.1) 
Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal 
Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg 
Every 6 Weeks 
• for use at an additional recommended dosage of 400 mg every 
6 weeks for Classical Hodgkin Lymphoma and Primary 
Mediastinal Large B-Cell Lymphoma in adults.2 (1.20, 2.2) 
1 This indication is approved under accelerated approval based on 
tumor response rate and durability of response. Continued 
approval for this indication may be contingent upon verification 
and description of clinical benefit in the confirmatory trials. 
2 This indication is approved under accelerated approval based on 
pharmacokinetic data, the relationship of exposure to efficacy, 
and the relationship of exposure to safety. Continued approval for 
this dosing may be contingent upon verification and description of 
clinical benefit in the confirmatory trials. 
-----------------------"
169,Intrahepatic Cholangiocarcinoma,Rearrangement,Futibatinib,"INDICATIONS AND USAGE--------------------------
LYTGOBI is a kinase inhibitor indicated for the treatment of adult patients 
with previously treated, unresectable, locally advanced or metastatic 
intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 
(FGFR2) gene fusions or other rearrangements. (1, 2.1) 
This indication is approved under accelerated approval based on overall 
response rate and duration of response. Continued approval for this indication 
may be contingent upon verification and description of clinical benefit in a 
confirmatory trial(s). (1) 
------------------------"
171,Acute Myeloid Leukemia,Somatic Variant,Olutasidenib,"INDICATIONS AND USAGE---------------------------
REZLIDHIA is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated 
for the treatment of adult patients with relapsed or refractory acute 
myeloid leukemia (AML) with a susceptible IDH1 mutation as detected 
by an FDA-approved test. (1) 
------------------------"
176,Non-Small Cell Lung Cancer,Somatic Variant,Adagrasib,"INDICATIONS AND USAGE _________________  
KRAZATI is an inhibitor of the RAS GTPase family indicated for the 
treatment of adult patients with KRAS G12C-mutated locally advanced or 
metastatic non-small cell lung cancer (NSCLC), as determined by an FDA 
approved test, who have received at least one prior systemic therapy. (1) 
This indication is approved under accelerated approval based on objective 
response rate (ORR) and duration of response (DOR). Continued approval for 
this indication may be contingent upon verification and description of a 
clinical benefit in a confirmatory trial(s). (1) 
  _______________"
178,Breast cancer,Somatic Variant,Elacestrant,"INDICATIONS AND USAGE----------------------------
ORSERDU is an estrogen receptor antagonist indicated for: 
• treatment of postmenopausal women or adult men, with ER-
positive, HER2-negative, ESR1-mutated advanced or metastatic 
breast cancer with disease progression following at least one line 
of endocrine therapy (1) 
-----------------------"
199,Prostate Cancer,Germline Variant,Abiraterone acetate + Niraparib,"INDICATIONS AND USAGE---------------------------
AKEEGA is a combination of niraparib, a poly (ADP-ribose) polymerase 
(PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with 
prednisone for the treatment of adult patients with deleterious or suspected 
deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate 
cancer (mCRPC). Select patients for therapy based on an FDA-approved test 
for AKEEGA. (1, 2.1) 
------------------------"
203,Endometrial cancer,Microsatellite Stability,Dostarlimab-gxly,"INDICATIONS AND USAGE---------------------------- Evaluate clinical chemistries, including liver enzymes, creatinine, and 
JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody thyroid function, at baseline and periodically during treatment. Withhold 
indicated: or permanently discontinue JEMPERLI and administer corticosteroids 
Endometrial Cancer (EC) based on the severity of reaction. (2.3, 5.1) 
• in combination with carboplatin and paclitaxel, followed by JEMPERLI • Infusion-related reactions: Interrupt, slow the rate of infusion, or 
as a single agent for the treatment of adult patients with primary advanced permanently discontinue JEMPERLI based on severity of reaction. (2.3, 
or recurrent endometrial cancer that is mismatch repair deficient 5.2) 
(dMMR), as determined by an FDA-approved test, or microsatellite • Complications of allogeneic hematopoietic stem cell transplantation instability-high (MSI-H). (1.1, 2.1) (HSCT): Fatal and other serious complications can occur in patients who 
• as a single agent for the treatment of adult patients with dMMR recurrent receive allogeneic HSCT before or after being treated with a 
or advanced endometrial cancer, as determined by an FDA-approved test, PD-1/PD-L1–blocking antibody. (5.3) 
that has progressed on or following prior treatment with a platinum- • Embryo-fetal toxicity: Can cause fetal harm. Advise females of containing regimen in any setting and are not candidates for curative reproductive potential of the potential risk to a fetus and to use effective surgery or radiation. (1.1, 2.1) contraception. (5.4, 8.1, 8.3) Mismatch Repair Deficient Recurrent or Advanced Solid Tumors 
• as a single agent for the treatment of adult patients with dMMR recurrent ------------------------------- ADVERSE REACTIONS ------------------------------
or advanced solid tumors, as determined by an FDA-approved test, that • Most common adverse reactions (≥20%) with JEMPERLI in 
have progressed on or following prior treatment and who have no combination with carboplatin and paclitaxel in patients with 
satisfactory alternative treatment options.1 (1, 2.1) dMMR/MSI-H EC are rash, diarrhea, hypothyroidism, and hypertension. 
1This indication is approved under accelerated approval based on tumor Most common Grade 3 or 4 laboratory abnormalities (≥10%) are 
response rate and durability of response. Continued approval for this decreased neutrophils, decreased hemoglobin, decreased white blood 
indication may be contingent upon verification and description of clinical cell count, decreased lymphocytes, increased glucose, decreased sodium, 
benefit in a confirmatory trial(s). (1) and decreased platelets. (6.1) 
• Most common adverse reactions (≥20%) with JEMPERLI as a single ------------------------"
209,Breast cancer,Somatic Variant,Capivasertib + Fulvestrant,"INDICATIONS AND USAGE --------------------------
TRUQAP is a kinase inhibitor indicated, in combination with fulvestrant for 
the treatment of adult patients with hormone receptor (HR)-positive, human 
epidermal growth factor receptor 2 (HER2)-negative, locally advanced or 
metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as 
detected by an FDA-approved test following progression on at least one 
endocrine-based regimen in the metastatic setting or recurrence on or within 
12 months of completing adjuvant therapy. (1) 
----------------------"
223,Non-Small Cell Lung Cancer,Somatic Variant,Tepotinib,"INDICATIONS AND USAGE---------------------------
TEPMETKO is a kinase inhibitor indicated for the treatment of adult patients 
with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-
epithelial transition (MET) exon 14 skipping alterations. (1) 
-----------------------"
227,Non-Small Cell Lung Cancer,Rearrangement,Repotrectinib,"INDICATIONS AND USAGE---------------------------
AUGTYRO is a kinase inhibitor indicated for the treatment of adult patients 
with locally advanced or metastatic ROS1-positive non-small cell lung cancer 
(NSCLC). (1) 
-----------------------"
229,Acute Lymphoblastic Leukemia,Rearrangement,Ponatinib + Chemotherapy,"INDICATIONS AND USAGE--------------------------- 
ICLUSIG is a kinase inhibitor indicated for the treatment of adult 
patients with: 
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 
(Ph+ ALL) 
• Newly diagnosed Ph+ ALL, in combination with chemotherapy. (1) 
This indication is approved under accelerated approval based on 
minimal residual disease (MRD)-negative complete remission 
(CR) at the end of induction. Continued approval for this 
indication may be contingent upon verification of clinical benefit in 
a confirmatory trial(s). 
• As monotherapy in Ph+ ALL for whom no other kinase inhibitors 
are indicated or T315I-positive Ph+ ALL. (1) 
Chronic Myeloid Leukemia (CML) 
• Chronic phase (CP) CML with resistance or intolerance to at least 
two prior kinase inhibitors. (1) 
• Accelerated phase (AP) or blast phase (BP) CML for whom no 
other kinase inhibitors are indicated. (1) 
• T315I-positive CML (chronic phase, accelerated phase, or blast 
phase). (1) 
Limitations of Use: ICLUSIG is not indicated and is not recommended 
for the treatment of patients with newly diagnosed CP-CML. (5.7) 
------------------------"
